AACR Annual Meeting 2024, San Diego, CA, April 5-10

‍

genOway’s program at AACR 2024

‍

Spotlight Theater workshop

Title: "Presence of myeloid and lymphoid cells are key for translational tumor biology, efficacy and safety assessment in humanized mouse models"‍

Summary:

• The presence of human myeloid and lymphoid compartments in preclinical humanized models contributes to their relevancy and translatability. As new therapeutic approaches co-target both compartments, this has become a key feature of drug development which is both critical and challenging, due to most mouse models exhibiting a short life-span and severe side effects when the myeloid compartment is induced.
• Our BRGSF-HIS model is an immunodeficient mouse which exhibits both functional human lymphoid and myeloid compartments.
• Human immune cell recruitment and activation into the TME is tumor-dependent, evidencing the functionality of the immune response in the BRGSF-HIS model.
• The assessment of TCE’s safety in the BRGSF-HIS model revealed that myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome (CRS) features in the model.
• The BRGSF-HIS model enables therapeutics’ MoA investigation.

Video recording:

‍

Our posters

Below are the four posters presented by our team at the conference:

#5292

Title: CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies — Our humanized CD28 mouse model allows for the assessment of CD28-targeting agents' efficacy and safety, facilitating studies on combination therapies and bispecific antibodies targeting CD3 and CD28.

#1530

Title: Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice — Our highly immunodeficient mouse model reconstituted with human cord blood CD34+ cells, BRGSF-HIS, provides a stable and permissive environment for studying cancer development and testing novel therapeutics, with response to treatment reflecting clinical heterogeneity and enabling further investigation of treatment mechanisms and immune escape.

#2045

Title: Novel TFRC humanized mouse model for drug delivery to the brain —  hTFRC was developed to assess compounds targeting human TFRC for delivery through the blood-brainbarrier (BBB) and the efficient shuttling of therapeutic antibodies to the brain.

#5341

Title: Novel FcγR humanized mouse models enable assessment of PK/PD of therapeutic antibodies — We developed a mouse model expressing humanized Fcγ receptors with a human-like expression pattern, enabling assessment of therapeutic antibodies' enhanced activity and functionality, with potential applications in evaluating Fc-engineered therapeutic antibodies and improving translatability in pharmacokinetic assessments.

‍

Our clients' posters

Below are posters presented by clients using our models:

• Cidara Therapeutics │ Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model
  Models used: PD-1/PD-L1 mouse and M38 hPD-L1-LZ cell line

• Bonum Therapeutics │ A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells
  ‍Model used: PD1/LAG3 mouse

• Sensei Bio │ Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy
  ‍Model used: CD28 mouse
  

‍

You can access more detailed information about the AACR 2024 here